Abstracts tagged "clinical trial"

Abstract Number: 1072 • ACR Convergence 2025
Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review
Manuel Carpio Tumba¹, Raisa Lomanto Silva², Lily Sung³, Laura C. Pedraza-Arévalo⁴, Sneha Gupta⁵, Jeenah Gwak⁶, Aida Mohamadi⁷, Diana Louden⁸, Rachael Stovall⁸, Namrata Singh⁹, Didem Saygin¹⁰, Sarah Lieber¹¹, Jiha Lee¹² and Sebastian E Sattui¹³, ¹University of Pittsburgh, Pittsburgh, PA, ²Massachusetts General Hospital, Boston, MA, ³Stanford University Hospital & Clinics, Hayward, CA, ⁴St. Barnabas Hospital, New York, NY, ⁵University of Pittsburgh Medical Center McKeesport, McKeesport, PA, ⁶Stanford University, Palo Alto, CA, ⁷Tehran University of Medical Sciences, Tehran, Iran, ⁸University of Washington, Seattle, WA, ⁹University of Washington, Bellevue, WA, ¹⁰Rush University Medical Center, Chicago, IL, ¹¹Hospital for Special Surgery, New York, NY, ¹²University of Michigan, Ann Arbor, MI, ¹³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A growing number of older adults are living with autoimmune rheumatic diseases (AIRDs) as the global population is aging. And yet, they remain underrepresented…
Abstract Number: 0640 • ACR Convergence 2025
Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
Vibeke Strand¹, Zahi Touma², Anca Askanase³, Christopher Saffore⁴, Denise Kruzikas⁵, Karim Masri⁵, Siran Fang⁵, Yi Peng⁶, Patti Katz⁷ and Marta Mosca⁸, ¹Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ²University of Toronto, Toronto, ON, Canada, ³Columbia University Medical Center, New York, NY, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Maple Grove, MN, ⁷UCSF, San Rafael, CA, ⁸University of Pisa, Pisa, Pisa, Italy
Background/Purpose: This analysis evaluated associations between clinically important improvements in patient-reported outcomes (PROs) and reduced disease activity from the phase 2 SLEek trial evaluating upadacitinib…
Abstract Number: 0816 • ACR Convergence 2025
Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs
Andreas Kerschbaumer¹, Marlene Steiner², William H. Robinson³, Josef Smolen⁴ and Daniel Aletaha⁵, ¹Stanford University / Medical University of Vienna, Stanford, CA, ²Medical University of Vienna, Vienna, Wien, Austria, ³Stanford University, Palo Alto, CA, ⁴Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Joint swelling and tenderness are clinical hallmarks of rheumatoid arthritis (RA) and central to disease assessment. Regardless of treatment type, stringent remission based on…
Abstract Number: 0470 • ACR Convergence 2025
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Peter Taylor¹, Yoshiya Tanaka², Louis Dron³, Katrien Van Beneden⁴, Gerd Burmester⁵ and Bruno Fautrel⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Cytel, Toronto, Canada, ⁴Alfasigma S.p.A., Bologna, Italy, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Janus kinase inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). Pain response trajectories were modeled…
Abstract Number: 2692 • ACR Convergence 2025
Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA)
Sophie De Mits¹, Tine Willems², Lieven Danneels², Patrick Calders², Gaëlle Varkas³, Filip Van den Bosch⁴, Dirk Elewaut⁵ and Philippe Carron⁶, ¹Ghent University Hospital, Gent, Belgium, ²Ghent University, Gent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁶Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: AxSpA primarily affects the sacroiliac joints and spine, reducing trunk strength, mobility, and cardiorespiratory fitness. While exercise is a key treatment, few studies have…
Abstract Number: 2452 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
Sanbin Wang¹, Heng Mei², Dongmei Zhou³, Wei Xie², Songlou Yin³, Chunmei Liu³, Hanwei Wang⁴, Huan Zhou⁵, Yue Xie⁶, Lu Han⁷, Jiangtao Ren⁸, Yali Zhou⁸, Wengang Ge⁷ and Jan Davidson-Moncada⁸, ¹⁹²⁰th Hospital of Joint Logistic Support Force, Kunming, China (People's Republic), ²Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ³The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China (People's Republic), ⁴The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), ⁶Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ⁷Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁸Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are autoimmune conditions characterized by B cell activation, autoreactivity, and autoantibody production. CAR-T therapy…
Abstract Number: 2307 • ACR Convergence 2025
Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
AUGUSTA ORTOLAN¹, Casper Webers², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Maastricht University Medical Centre, Maastricht, Netherlands, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Peripheral manifestations (peripheral arthritis, enthesitis, dactylitis) of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) represent a significant burden for patients, but are understudied. Our…
Abstract Number: 2014 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…
Abstract Number: 1564 • ACR Convergence 2025
Validation of a Composite Endpoint for Systemic Sclerosis-Associated Interstitial Lung Disease
Elizabeth Volkmann¹, Holly Wilhalme², Samuel Good², Grace Kim², Jonathan Goldin², Michael Roth² and Donald Tashkin², ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²UCLA, Los Angeles
Background/Purpose: The forced vital capacity (FVC) is the most commonly used endpoint in registrational trials for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, the FVC…
Abstract Number: 1447 • ACR Convergence 2025
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Ulrich Mrowietz¹, Laura Coates², Diamant Thaçi³, Mark Lebwohl⁴, Bardur Sigurgeirsson⁵, Richard B. Warren⁶, Richard G. Langley⁷, Andreas Clemens⁸, Cynthia Vizcaya⁸, Weibin Bao⁹, Kim Hoyt¹⁰, Lara Gómez¹¹ and Robert Bissonnette¹², ¹Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵University of Iceland, Faculty of Medicine, Department of Dermatology,, Reykjavik, Iceland, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Farmaceutica, Madrid, Spain, ¹²Innovaderm, Montreal, Québec, Canada
Background/Purpose: Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A, demonstrating robust and sustained efficacy in moderate to severe psoriasis (PsO) and psoriatic…
Abstract Number: 1051 • ACR Convergence 2025
Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
Isabella Hartel¹, David Gazeley², Jay Patel¹, Betty Chewning³, Shelby Gomez⁴, Jessica Michaud⁵, Laura Dickmann⁶, Jon keevil⁷, Patricia Tellez-giron¹, Christie Bartels⁸ and Shivani Garg⁹, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Wisconsin, School of Pharmacy, Madison, ⁴University of Wisconsin, School of Pharmacy, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, Madison, WI, ⁶Medical College of Wisconsin, Milwaukee, Milwaukee, ⁷N/A, Madison, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁹University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) prolongs disease-free and damage-free survival in lupus (SLE). Yet, ~80% of patients stop taking HCQ resulting in poor outcomes including early mortality.…
Abstract Number: 0590 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Vinod Chandran¹, Oliver FitzGerald², Philip J. Mease³, Lihi Eder⁴, Jose Scher⁵, Christopher Ritchlin⁶, Dafna D. Gladman⁷, Walter P Maksymowych⁸, Coryandar Gilvary⁹, Aditi Basu Bal⁹, Eleni Vritzali¹⁰ and Jinqi Liu⁹, ¹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ²UCD, Dublin ⁶, Dublin, Ireland, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto, ON, Canada, ⁵New York University School of Medicine, New York, NY, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Understanding how treatments affect disease-relevant biomarker expression is essential for advancing targeted therapies. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, has…
Abstract Number: 0803 • ACR Convergence 2025
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, ⁴GSK, Biostatistics, London, United Kingdom, ⁵Global Medical Affairs, GSK, Dublin, Ireland, ⁶GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Padova, Italy
Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
Abstract Number: 0405 • ACR Convergence 2025
Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study
Hermine Brunner¹, Ivan Foeldvari², Gerd Horneff³, Antonio Mera Varela⁴, Angelo Ravelli⁵, Sharonjeet Kaur⁶, Swapnil Suhas Dahale⁷, Ruvie Martin⁸, Daniel Lovell¹, Alberto Martini⁹ and Nicolino Ruperto¹⁰, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, ³Asklepios Klinik, Hamburg, Germany, ⁴Rheumatology Division. Hospital Clínico Universitario de Santiago and Instituto de Investigaciones Sanitarias (IDIS), School of Medicine, Santiago de Compostela, Spain, ⁵IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷IQVIA, Mumbai, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Università di Genova, Genova, Italy, ¹⁰Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy
Background/Purpose: Secukinumab demonstrated efficacy and safety in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), for up to…
Abstract Number: 2671 • ACR Convergence 2025
Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
Rohit Aggarwal¹, Sebastian Rodriguez-Garcia², Agna Neto³, Despoina Papadopoulou⁴, Ben Van Baelen³, Paul Duncombe³, Leentje De Ceuninck⁵, Bas van der Woning⁶ and Hector Chinoy⁷, ¹University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ²Hospital Universitario de La Princesa, Madrid, Spain, ³argenx, Ghent, Belgium, ⁴argenx, Alimos Attikis, Greece, ⁵argenx, Issy-les-Moulineaux, France, ⁶argenx BV, Boston, MA, ⁷The University of Manchester, Manchester, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare, systemic, autoimmune, rheumatic disease, with different subtypes, characterized by muscle weakness and extra-muscular involvement. There are no…

« Previous Page
1
…
6
7
8
9
10
…
55
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].